Does Rallies show 13F holders for NVCR?

Yes. Rallies tracks hedge fund and 13F ownership data for NVCR, including fund names, share counts, latest tracked quarter, and position changes when available.

Is NVCR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NVCR. It does not provide personalized investment advice.

NVCR (NovoCure Limited Ordinary Shares) Stock Analysis - Hedge Fund Holdings

NovoCure Limited Ordinary Shares (NVCR) is a publicly traded Healthcare sector company. As of May 21, 2026, NVCR trades at $17.60 with a market cap of $2.02B and a P/E ratio of -14.46. NVCR moved +4.29% today. Year to date, NVCR is +28.90%; over the trailing twelve months it is -2.47%. Its 52-week range spans $9.82 to $34.13. Analyst consensus is buy with an average price target of $26.17. Rallies surfaces NVCR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns NVCR stock?

Hedge funds tracked by Rallies that own NVCR include Coatue Management, Panagora Asset, Berkshire Asset, and Bridgewater Associates. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for NovoCure Limited Ordinary Shares.

NVCR Key Metrics

Key financial metrics for NVCR
Metric	Value
Price	$17.60
Market Cap	$2.02B
P/E Ratio	-14.46
EPS	$-1.22
Dividend Yield	0.00%
52-Week High	$34.13
52-Week Low	$9.82
Volume	29
Avg Volume	0
Revenue (TTM)	$655.35M
Net Income	$-136.23M
Gross Margin	74.54%

Top Hedge Funds Holding NVCR

Coatue Management holds 608.67K shares of NVCR, changed +0.00% as of Mar 31, 2025.
Panagora Asset holds 77.12K shares of NVCR, changed -7.44% as of Mar 31, 2026.
Berkshire Asset holds 15.00K shares of NVCR, changed +0.00% as of Sep 30, 2024.
Bridgewater Associates holds 11.12K shares of NVCR, changed -71.77% as of Dec 31, 2024.

Latest NVCR News

Japan Grants National Insurance Reimbursement for Optune Lua NSCLC Treatment — Mar 9, 2026
NovoCure Q4 Loss Narrows to $0.22 EPS, Beats Estimates — Feb 26, 2026
Novocure’s Optune Pax Approved by FDA for Locally Advanced Pancreatic Cancer — Feb 25, 2026
Novocure Gains 37% on Pancreatic Cancer Device Clearance; Soleus Boosts Celcuity Stake — Feb 13, 2026
Novocure’s Optune Pax FDA Approval Boosts Pancreatic Cancer Survival by Two Months — Feb 12, 2026

Recent NVCR Insider Trades

Paravasthu Mukund sold 43.25K (~$595.67K) on Mar 5, 2026.
Leupin Nicolas sold 1.10K (~$14.64K) on Mar 4, 2026.
Weinberg Uri sold 6.41K (~$85.31K) on Mar 4, 2026.

NVCR Analyst Consensus

6 analysts cover NVCR: 0 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $26.17.

Common questions about NVCR

Who owns NVCR stock?: Hedge funds tracked by Rallies that own NVCR include Coatue Management, Panagora Asset, Berkshire Asset, and Bridgewater Associates. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for NovoCure Limited Ordinary Shares.
Does Rallies show 13F holders for NVCR?: Yes. Rallies tracks hedge fund and 13F ownership data for NVCR, including fund names, share counts, latest tracked quarter, and position changes when available.
Is NVCR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NVCR. It does not provide personalized investment advice.